Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice

Anticancer Research

Volumn 27, Issue 1 A, 2007, Pages 299-308

  Lee, Intae ^a   Kalota, Anna ^a   Gewirtz, Alan M ^a   Shogen, Kuslima ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Alfacell Corporation   (United States)

Author keywords

Cisplatin; Cytotoxic RNase; Lung cancer; Onconase ; Ranpirnase

Indexed keywords

ADENOSINE TRIPHOSPHATE; CISPLATIN; RANPIRNASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER MODEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE SEQUENCE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; UNSPECIFIED SIDE EFFECT; XENOGRAFT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; RIBONUCLEASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33847616665     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Rybak SM and Newton DL: Natural and engineered cytotoxic ribonucleases: therapeutic potential. Experimental Cell Res 253: 325-335, 1999.
2. Rutkoski TJ, Kurten EL, Mitchell JC and Raines RT: Disruption of shape-complementary markers to create cytotoxic variants of ribonuclease A. J Mol Biol 354: 41-54, 2005.
3. Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, Mittelman A, Panella T, Puccio C, Fine R and Shogen K: Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20: 274-281, 2001.
4. Costanzi J, Sidransky D, Navon A and Goldsweig H: Ribonucleases as a novel pro-apoptonic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest 3: 643-650, 2005.
5. Iordanov MS, Ryabinina OP, Wong J, Dinh TH, Newton DL, Rybak SM and Magun BE: Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis. Cancer Res 60: 1983-1994, 2000.
6. Saxena SK, Sirdeshmukh R, Ardelts W, Mikulski SM, Shogen K and Youle RJ: Entry into cells and selective degradation of tRNA by a cytotoxic member of the RNase A family. J Biol Chem 277: 15142-15146, 2002.
7. Kim DH, Kim EJ, Kalota A, Gewirtz AM, Glickson J, Shogen K and Lee I: Possible mechanisms of improved radiation response by cytotoxic RNase, ONCONASE®, on A549 human lung cancer xenografts of nude mice. Adv Exp Med Biol, in press, 2006.
8. Lee I, Lee YH, Mikulski SM, Lee J, Covone K and Shogen K: Tumoricidal effects of onconase on various tumors. J Surgical Oncology 73: 164-171, 2000.
9. He C, Shungu DC, van Zijl PCM, Bhujwalla ZM and Glickson JD: Single-scan in vivo lactate editing with complete lipid and water suppression by selective multiple-quantum-coherence transfer (Sel-MQC) with application to tumors. JMR 105(Series B): 203-211, 1995.
10. Boas DA, O'Leary MA, Chance B and Yodh AG: Scattering of diffuse photon density waves by spherical inhomogeneities within turbid media: analytic solution and applications. Proc Natl Acad Sci USA 91: 4887-4891, 1994.
11. Grabarek J, Ardelt B, Du L and Darzynkiewicz Z: Activation of caspases and serine proteases during apoptosis induced by onconase (ranpirnase). Exp Cell 278: 61-71, 2002.
12. L858R non-small cell lung cancer line H3255. Cancer Res 64: 7241-7244, 2004.
13. Sordella R, Bell DW, Harber DA and Settleman J: Gefitinib-sensitizing EFGR mutations in lung cancer activate anti-apoptotic pathway. Science 305: 1163-1167, 2004.
14. Lee I, Lee YH, Mikulski SM and Shogen K: Effect of onconase± tamoxifen on AsPC-1 human pancreatic tumors in nude mice. Adv Exp Med Biol 530: 187-196, 2003.
15. Lee I, Lee YH, Mikulski SM, Lee J and Shogen K: Enhanced cellular radiation sensitivity of androgen-independent human prostate tumor cells by onconase. Anticancer Res 20: 1037-1040, 2000.
16. Lee I, Boucher Y and Jain RK: Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res 52: 3237-3240, 1992.
17. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.